Patent US5651986A successfully refreshed from Google Patents.
US5651986A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled local delivery of chemotherapeutic agents for treating solid tumors
Assignee: Johns Hopkins University
•
Filing: 1996-06-14
•
Granted: 1997-07-29
•
Expires: 2016-06-14
Abstract
Abstract A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel and camptothecin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.
Inventors
- 👤 Henry Brem
- 👤 Robert S. Langer
- 👤 Abraham J. Domb
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 13:18
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0085; A61K31/00; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/435; A61K31/47; A61K31/4738; A61K31/4745; A61K31/555; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/2031; A61K9/204; A61P; A61P35/00
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
75 words
A chemotherapeutic composition comprising a biocompatible synthetic polymeric matrix incorporating an effective amount to inhibit tumor growth when released in vivo at the site of the tumor of a water insoluble, relatively lipid insoluble chemotherapeutic agent, wherein the chemotherapeutic agent is incorporated into and released from a synthetic polymeric matrix by degradation of the polymer matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours.
Claim 2
Dependent Claim
75 words
A chemotherapeutic composition comprising a biocompatible synthetic polymeric matrix incorporating an effective amount to inhibit tumor growth when released in vivo at the site of the tumor of a water insoluble, relatively lipid insoluble chemotherapeutic agent, wherein the chemotherapeutic agent is incorporated into and released from a synthetic polymeric matrix by degradation of the polymer matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours.
Claim 3
Dependent Claim
16 words
The composition of claim 1 wherein the chemotherapeutic agent is paclitaxel or a functionally effective derivative.
Claim 4
Dependent Claim
16 words
The composition of claim 1 wherein the chemotherapeutic agent is camptothecin or a functionally effective derivative.
Claim 5
Dependent Claim
11 words
The composition of claim 1 wherein the polymer matrix is biodegradable.
Claim 6
Dependent Claim
33 words
The composition of claim 4 wherein the polymeric matrix is formed of a hydrophobic polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, polyphosphazenes, polyorthoesters, polyesters, polyamides, polysaccharides, copolymers and blends thereof.
Claim 7
Dependent Claim
15 words
The composition of claim 1 wherein the polymeric matrix is formed of ethylene vinyl acetate.
Claim 8
Dependent Claim
36 words
The composition of claim 1 further comprising additional biologically active compounds selected from the group consisting of other chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
Claim 9
Independent Claim
92 words
A method of administering to a patient in need of treatment a water insoluble, relatively lipid insoluble chemotherapeutic agent comprising administering an amount of the chemotherapeutic agent effective to inhibit growth of a solid tumor, wherein the systemic administration of the same dosage of chemotherapeutic agent is not effective to treat tumors, and wherein the chemotherapeutic agent is incorporated into and released from a synthetic polymeric matrix by degradation of the polymer matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours.
Claim 10
Independent Claim
92 words
A method of administering to a patient in need of treatment a water insoluble, relatively lipid insoluble chemotherapeutic agent comprising administering an amount of the chemotherapeutic agent effective to inhibit growth of a solid tumor, wherein the systemic administration of the same dosage of chemotherapeutic agent is not effective to treat tumors, and wherein the chemotherapeutic agent is incorporated into and released from a synthetic polymeric matrix by degradation of the polymer matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours.
Claim 11
Dependent Claim
16 words
The method of claim 8 wherein the chemotherapeutic agent is paclitaxel or a functionally effective derivative.
Claim 12
Dependent Claim
16 words
The method of claim 8 wherein the chemotherapeutic agent is camptothecin or a functionally effective derivative.
Claim 13
Dependent Claim
21 words
The method of claim 8 wherein the chemotherapeutic agent is locally delivered by direct infusion to the tumor from a reservoir.
Claim 14
Dependent Claim
23 words
The method of claim 8 wherein the chemotherapeutic agent is locally delivered by implantation of a biocompatible polymer matrix incorporating the chemotherapeutic agent.
Claim 15
Dependent Claim
11 words
The method of claim 8 wherein the polymer matrix is biodegradable.
Claim 16
Dependent Claim
33 words
The method of claim 13 wherein the polymeric matrix is formed of a hydrophobic polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, polyphosphazenes, polyorthoesters, polyesters, polyamides, polysaccharides, copolymers and blends thereof.
Claim 17
Dependent Claim
15 words
The method of claim 8 wherein the polymeric matrix is formed of ethylene vinyl acetate.
Claim 18
Dependent Claim
14 words
The method of claim 8 further comprising administering radiation in combination with the composition.
Claim 19
Dependent Claim
41 words
The method of claim 8 further comprising administering with the chemotherapeutic agent additional biologically active compounds selected from the group consisting of other chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
Claim 20
Dependent Claim
21 words
The method of claim 8 wherein the composition is in the form of micro-implants and are administered by injection or infusion.
Claim 21
Dependent Claim
16 words
The composition of claim 1 wherein the chemotherapeutic is released with linear or first order kinetics.
Claim 22
Dependent Claim
16 words
The composition of claim 5 wherein the chemotherapeutic agent is paclitaxel or a functionally effective derivative.
Claim 23
Dependent Claim
16 words
The composition of claim 5 wherein the chemotherapeutic agent is camptothecin or a functionally effective derivative.
Claim 24
Dependent Claim
16 words
The method of claim 8 wherein the chemotherapeutic is released with linear or first order kinetics.
Claim 25
Dependent Claim
16 words
The method of claim 14 wherein the chemotherapeutic agent is paclitaxel or a functionally effective derivative.
Claim 26
Dependent Claim
16 words
The method of claim 14 wherein the chemotherapeutic agent is camptothecin or a functionally effective derivative.
Claim 27
Dependent Claim
75 words
A chemotherapeutic composition comprising a chemotherapeutic agent incorporated into a synthetic polymeric matrix releasing the chemotherapeutic by diffusion or degradation over a period of at least eight hours in an amount effective to treat brain tumors, wherein the chemotherapeutic agent is selected from the group consisting of carboplatinum, adriamycin, ternozolamide, vincristine, etoposide, cytokines, DNA or RNA including oligonucleotides, ribozymes, and guide sequences for ribozymes which inhibit translation or transciption of essential tumor genes, and dacarbazine.
Claim 28
Dependent Claim
75 words
A chemotherapeutic composition comprising a chemotherapeutic agent incorporated into a synthetic polymeric matrix releasing the chemotherapeutic by diffusion or degradation over a period of at least eight hours in an amount effective to treat brain tumors, wherein the chemotherapeutic agent is selected from the group consisting of carboplatinum, adriamycin, ternozolamide, vincristine, etoposide, cytokines, DNA or RNA including oligonucleotides, ribozymes, and guide sequences for ribozymes which inhibit translation or transciption of essential tumor genes, and dacarbazine.
Claim 29
Dependent Claim
40 words
The composition of claim 25 wherein the composition further comprises an additional biologically active compound selected from the group consisting of other chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
Claim 30
Dependent Claim
10 words
The composition of claim 25 wherein the compound is adriamycin.
Claim 31
Dependent Claim
10 words
The composition of claim 25 wherein the compound is carboplatinum.
Claim 32
Dependent Claim
11 words
The composition of claim 25 wherein the compound is a cytokine.
Claim 33
Independent Claim
88 words
A method for treating brain tumors comprising administering at a site in a patient in need of treatment a chemotherapeutic composition having incorporated into a synthetic polymeric matrix releasing the chemotherapeutic by diffusion or degradation over a period of at least eight hours in an amount effective to treat brain tumors a chemotherapeutic agent selected from the group consisting of carboplatinum, adriamycin, ternozolamide, vincristine, etoposide, cytokines, DNA or RNA including oligonucleotides, ribozymes, and guide sequences for ribozymes which inhibit translation or transciption of essential tumor genes, and dacarbazine.
Claim 34
Independent Claim
88 words
A method for treating brain tumors comprising administering at a site in a patient in need of treatment a chemotherapeutic composition having incorporated into a synthetic polymeric matrix releasing the chemotherapeutic by diffusion or degradation over a period of at least eight hours in an amount effective to treat brain tumors a chemotherapeutic agent selected from the group consisting of carboplatinum, adriamycin, ternozolamide, vincristine, etoposide, cytokines, DNA or RNA including oligonucleotides, ribozymes, and guide sequences for ribozymes which inhibit translation or transciption of essential tumor genes, and dacarbazine.
Claim 35
Dependent Claim
42 words
The method of claim 30 further comprising administering with the chemotherapeutic composition an additional biologically active compound selected from the group consisting of other chemotherapeutics, antibiotics, antivirals, antiinflamatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
Claim 36
Dependent Claim
10 words
The method of claim 30 wherein the compound is adriamycin.
Claim 37
Dependent Claim
10 words
The method of claim 30 wherein the compound is carboplatinum.
Claim 38
Dependent Claim
11 words
The method of claim 30 wherein the compound is a cytokine.
References Cited (Backward Citations)
US5145684A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-07-28 | 2001-01-27 | 2001-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-07-28 | 2005-01-27 | 2005-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-07-28 | 2009-01-27 | 2009-07-29 | $7700.00 | Window Closed / Lapsed |